Code of conduct

This Code of Conduct is the first step to showing dedication to upholding continuous excellence in both business and ethical terms, and showing our care and dedication to products, clients and success.

Polpharma Biologics i Uniwersytet Warszawski podpisują umowę o współpracy – to kolejny krok ku międzynarodowej platformie współpracy naukowej tworzonej przez firmę.

Jerzy Starak’s billions invested in Polpharma Biologics are going to soon bear fruit in the form of new biosimilar drugs.

Polpharma Biologics is a fast-growing business that develops and manufactures biopharmaceuticals as new molecular entities (NMEs) or biosimilars, and also delivers biopharmaceutical CDMO services.

Boost Your Career With Us

Polpharma Biologics podpisała globalną umowę na komercjalizację leku biopodobnego do natalizumabu – kluczowego leku w terapii stwardnienia rozsianego

Process optimisation for biologics is obligatory for efficient processing and reduction of Cost of Goods (COGs). Especially in the development of biosimilar antibodies, low COGs to manufacture the antibody provides a competitive advantage compared to competing biosimilar developers.

Polpharmа Biologics Group conducts business in compliance with the highest ethical standards, adhering to its established system of values which is based on compliance, honesty, responsibility and cooperation.

Building a biologics business from the ground up provides tremendous flexibility but requires the right business strategy. Polpharma has attracted worldrecognized leaders to build and manage all key biologics funcions at its new, state-of-the-art facilities, which are located in Poland and in the Netherlands, ideally situated to serve the global markets.